Biopharmaceutics Closes Drug Manufacturing Operations

Biopharmaceutics, Inc. has terminated all production at its generic and contract pharmaceuticals division. Jonathan Rosen, acting president and CEO, explained that the drug manufacturing division does not fit with the Company's overall strategy for growth. The liquidation of the drug manufacturing division will eliminate Biopharmaceutics' unnecessary secured debt and allow the Company's Board to press on with its consolidation plans.

"This closure will allow us to focus solely on the development and sales growth of our feminine hygiene branded product lines," said Rosen, "concentrating our efforts on generating profit in the multi-billion dollar feminine health market."

In addition to concentrating on its feminine hygiene branded products, Biopharmaceutics is also continuing with its plans to develop its DBD/Mitolactol brain cancer drug. The Company's Board of Directors has determined to provide up to $1 million in equity capital to be contributed at a 20% premium to the current market price for the Company's shares.

For more information: Jonathan Rosen, acting president and CEO, Biopharmaceutics, Inc., 990 Station Rd., Bellport, NY 11713. Telephone: 516-286-5800. Fax: 516-286-5803.